Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link

Volume 8, Number 5—May 2002

Perspective

Evaluation in Nonhuman Primates of Vaccines against Ebola Virus

Thomas W. Geisbert*, Peter Pushko*, Kevin Anderson*, Jonathan Smith*, Kelly J. Davis*, and Peter B. Jahrling*
Author affiliations: *U.S. Army Medical Research Institute of Infectious Diseases, Fort Detrick, Maryland, USA

Main Article

Table 2

Challenge of vaccinated monkeys with Ebola virus (EBOV)

NHP Species Vector Antigen Survival/total Viremic/total Day of deatha
Cynomolgus Replicon GP 0/3 3/3 6, 6, 7
Cynomolgus Replicon NP 0/3 3/3 6, 6, 7
Cynomolgus Replicon GP + NP 0/3 3/3 6, 6, 7
Cynomolgus Replicon Influenza HA 0/3 3/3 6, 6, 7
Cynomolgus Vaccinia GP 0/3 3/3 6, 7, 7
Cynomolgus Liposome Inactivated virion 0/3 3/3 7, 7, 11
Cynomolgus Inactivated virion 0/2 2/2 6, 6
Rhesus Inactivated virion 1/2 2/2 9
Cynomolgus None 0/2 2/2 6, 7
Rhesus None 0/2 2/2 8, 9

aNumber of days after challenge with 1,000 PFU of EBOV.
NHP, nonhuman primate; GP, glycoprotein; NP, nucleoprotein.

Main Article

Page created: April 18, 2012
Page updated: April 18, 2012
Page reviewed: April 18, 2012
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external